Dealmaking from Elsevier Business Intelligence

Deals Shaping The Medical Industry, June 2013

Wed, 05 Jun 2013 11:15:04 -0400

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

Biopharma Dealmaking Quarterly Statistics, Q1 2013

Thu, 23 May 2013 00:00:29 -0400

Biopharma financing reached $4.6 billion in Q1 2013, exceeding Q4 2012’s $4.2 billion total, mostly through follow-on public offerings, which made up 47% of the total funding. Conversely, M&A was on the decline with 18 completed transactions together valued at $4.8 billion, the lowest quarter since 2009.

Deals Of The Week: Keeping Score – Valeant Wants Actavis, Which Covets Warner Chilcott …

Mon, 20 May 2013 00:01:25 -0400

Meanwhile, companies like Mylan and Novartis also reportedly have joined the Actavis chase. In addition, there’s been deal-making news from Elan and Theravance, Merck-Serono and Quintiles, and AbbVie and Alvine.

IN VIVO: Deals Shaping The Medical Industry, May 2013

Fri, 03 May 2013 11:45:06 -0400

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

Schizophrenia Dominates Psychiatric Drug Deal-Making Since 2008

Mon, 29 Apr 2013 00:00:19 -0400

Of 34 deals in the psychiatric disorder space since 2008, none have been mergers and acquisitions, but two-thirds of such transactions have involved licensing of compounds before regulatory approval. The major deals in the space have been a multi-compound collaboration between Otsuka and Lundbeck and the failed tie-up between AstraZeneca and Targacept.

Versant Ventures Looks To Canada, Europe For New Deals

Fri, 12 Apr 2013 13:30:00 -0400

Hoping to boost its international dealmaking, the California venture firm is setting up shop in Vancouver, BC, and expanding in Switzerland, to gain access to emerging projects that haven’t been “picked over.”

Behind Closed Doors: Medtronic Exec Discusses Dealmaking In China

Tue, 02 Apr 2013 03:40:01 -0400

Medtronic’s dealmaking experience in China sheds light on how multinational players should think about entering China, but time may not be on their side.

Deals Shaping The Medical Industry, April 2013

Mon, 01 Apr 2013 13:00:00 -0400

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

[ChromaDex] gets rights to [Washington Univ.] patents covering nicotinamide riboside vitamin

Thu, 21 Mar 2013 19:01:00 -0400

Natural ingredients maker [ChromaDex Corp.] has received exclusive global rights to [Washington University]’s patents protecting nicotinamide riboside (NR), a vitamin for the prevention or treatment of neuropathies due to axon degeneration, which is involved in axon segment self-destruction and contributes to neurological symptoms in many conditions including diabetes, stroke, neurodegenerative diseases, or chemotherapy-induced neuropathy. ChromaDex also has rights to sublicense the IP.

Pharmas Among Biggest Cash Hoarders, Moody’s Finds

Wed, 20 Mar 2013 18:05:00 -0400

A Moody’s report lists seven pharmas among the 50 non-financial companies sitting on the largest piles of cash. These very big war chests hold the preferred currency, particularly for ex-U.S.pharma deal-making.

Onyx Provides Detail On Frontline Strategy For Kyprolis

Fri, 15 Mar 2013 18:05:00 -0400

Onyx supplied details about its clinical plans to enable frontline approval for Kyprolis to treat multiple myeloma and to effectively compete against well-established proteasome inhibitor competitor Velcade. It also elaborated further on its pipeline plans and deal-making strategy at an analyst day on March 14.

Deals Of The Week Untangles The String Of Pearls

Mon, 11 Mar 2013 00:01:08 -0400

In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.

[Cubist] gets rights to [Heptares]’ compounds against GPCRs

Thu, 07 Mar 2013 19:01:28 -0500

In partnership with GPCR drug discovery firm [Heptares Therapeutics Ltd.], [Cubist Pharmaceuticals Inc.] (acute care medicines) has received exclusive global rights to develop and market therapeutics against undisclosed GPCRs.

Belgian and US investors come together in €31.5mm PIPE for [Ablynx]

Tue, 05 Mar 2013 19:01:25 -0500

[Ablynx NV], creator of the {Nanobodies} single-domain antibody fragment platform, has raised €31.5mm ($41.2mm) from Belgian and US institutional and qualified investors, who bought 4.4mm shares at €7.20, a 7% discount. (Pre-IPO shareholders and warrant holders additionally sold 1.9mm shares at the same price.) The biotech more than beat its targeted gross proceeds of €20mm. Ablynx’s board terminated existing stockholders’ preferential subscription rights due to this transaction. The placement agents were KBC Securities, Bryan, Garnier & Co., and Nomura Code Securities. The new funding will allow the company to review future plans for lead rheumatoid arthritis candidate ALX0061 (positive safety and efficacy Phase II results were just announced); evaluate dealmaking structures for caplacizumab (in Phase II for thrombotic thrombocytopenic purpura) and ALX0171 (Phase I for respiratory syncytial virus); and work on preclinical studies for wholly or co-owned projects.

Deals Shaping The Medical Industry, March 2013

Mon, 04 Mar 2013 17:00:01 -0500

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

Deals Of The Week: Alnylam/The Medicines Co., Inspiration/Cangene, Pfizer/OxOnc

Mon, 11 Feb 2013 00:01:15 -0500

Biogen brings Tysabri fully in-house by using off-shore cash to compensate Irish partner Elan. Plus, the week in biopharma deal-making.

Biopharma Dealmaking Quarterly Statistics, Q4 2012

Thu, 07 Feb 2013 11:00:01 -0500

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions.

Deals Shaping The Medical Industry, February 2013

Tue, 05 Feb 2013 11:50:27 -0500

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

[Teva] sets up South Korean joint venture with [Handok]

Tue, 15 Jan 2013 19:02:00 -0500

[Teva Pharmaceutical Industries Ltd.] has set up a joint venture with [Handok Pharmaceuticals Co. Ltd.] (prescription and OTC products, and glucose monitoring systems) to market branded generic drugs, including specialty therapeutics and biosimilars, in South Korea.

Deals Shaping The Medical Industry, January 2013

Wed, 09 Jan 2013 13:16:13 -0500

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Pharmaceuticals, and Medical Devices – and then categorized by type –Acquisition, Alliance, or Financing.

In 2012, Buyer’s Market Made Alliances Rarer

Mon, 07 Jan 2013 00:01:41 -0500

With little leverage against Big Pharma, some smaller companies are turning away from long-standing partnering strategies. It’s one reason dealmaking slowed considerably in 2012, part of a three-year trend that also highlights increasing reliance on heavily structured partnerships.

Deals Of The Week: Roche/Cellular Dynamics, Pfizer/Philogen, Takeda/Amylin

Mon, 07 Jan 2013 00:01:30 -0500

Epizyme/Celgene, Amylin/BMS/AstraZeneca and Foundation Medicine garner readers’ huzzahs in our 2012 Deals of the Year poll. Plus Roche, Pfizer and Sanofi Pasteur start off 2013’s deal-making.

[Pernix] issues $25mm in stock to buy {Silenor} marketer [Somaxon Pharmaceuticals]

Wed, 19 Dec 2012 19:01:00 -0500

[Pernix Therapeutics Holdings Inc.] (brand, generic, and OTC products) is issuing $25mm of its common stock--about 3.4mm shares based on the ten-day average--to acquire publicly traded spec pharmaco [Somaxon Pharmaceuticals Inc.], which has been evaluating strategic alternatives since December 2011.

Pharma Deals That Generate Lasting Value: A Roundtable Discussion

Wed, 19 Dec 2012 10:53:00 -0500

At Elsevier Business Intelligence's recent Therapeutic Area Partnerships conference, a roundtable of senior pharmaceutical executives and entrepreneurs weighed in on industry’s current funding challenges, how dealmaking defines a biotech’s ambitions and strategy, and pharma’s appetite for early-stage innovation.

Deals Shaping The Medical Industry, December 2012

Tue, 18 Dec 2012 15:36:12 -0500

Derived from Strategic Transactions, EBI’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals– and then categorized by type –Acquisition, Alliance, or Financing.

Corruption Laws Take Front Seat In Asian Deal Making Decisions And Expansion Plans

Fri, 07 Dec 2012 08:06:02 -0500

Multinational firms in Asia need to consider building independent in-house compliance teams to guard against mistakes in handling corruption cases, compliance and risk management, experts advise.

The Orphan Drug Boom: Gold Rush Or Flash In The Pan?

Mon, 26 Nov 2012 00:30:00 -0500

Rare disease drug development has ballooned in just three years, powered by the success of independent biotechs like Alexion, Big Pharma’s entrée into the field, and pressure from regulators and payors that is dis-incentivizing development of traditional primary care drugs. The positive momentum has intensified dealmaking in the orphan drug space and is giving investors confidence to back rare disease-focused start-ups.

Deals Shaping The Medical Industry, November 2012

Mon, 26 Nov 2012 00:00:00 -0500

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents.

Biopharma Dealmaking Quarterly Statistics, Q3 2012

Mon, 26 Nov 2012 00:00:00 -0500

Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars.

Periphagen Holdings completes management buy-out of [Diamyd Inc.]

Fri, 16 Nov 2012 19:01:00 -0500

Existing management of [Diamyd Inc.] have formed Periphagen Holdings and bought out the US drug delivery division from its parent, Swedish biotech [Diamyd Medical AB].

Deals Of The Week: Vertex/GSK, Vertex/Janssen, Boehringer Ingelheim/Ensemble

Mon, 05 Nov 2012 00:00:00 -0500

Disparate events including Hurricane Sandy, extended-release generics, drug compounding and biopharma deal-making each highlighted just how important a challenge quality has become in the industry.

Deals Shaping The Medical Industry, October 2012

Mon, 22 Oct 2012 00:00:00 -0400

Join us at the 7th Annual Therapeutic Area Partnerships at the Westin Copley Place, Boston on November 28-30, 2012

Mon, 08 Oct 2012 00:00:00 -0400

TAP promises to deliver expert analysis of trends and opportunities in licensing and dealmaking, information on emerging biomedical opportunities, strategies for leading, financing and partnering, insights into fast-changing therapeutic areas and much more! Valuable networking opportunities from casual gatherings to one-on-one partnering meetings bring together top-level peers from around the globe to make this one of the industry's most dynamic events.

Publisher’s Spotlight: Therapeutic Area Partnerships Conference In Boston Nov. 28-30

Wed, 26 Sep 2012 14:00:00 -0400

Companion Diagnostics And Deal-making On The Stage At PSA

Thu, 20 Sep 2012 17:42:41 -0400

Panelists at Elsevier’s Pharmaceutical Strategic Alliances conference say the need for companion diagnostics and biomarkers, particularly in oncology, are influencing deal-making negotiations and raising questions about how to define the value of a diagnostic test relative to the therapeutic.

Join us at the 7^th Annual Therapeutic Area Partnerships at the Westin Copley Place, Boston on November 28-30, 2012

Thu, 13 Sep 2012 00:00:00 -0400

Join us at the 7^th Annual Therapeutic Area Partnerships at the Westin Copley Place, Boston on November 28-30, 2012

Wed, 12 Sep 2012 00:00:00 -0400

Deals Shaping The Medical Industry, September 2012

Wed, 12 Sep 2012 00:00:00 -0400

Deals Shaping The Medical Industry, July-August 2012

Mon, 30 Jul 2012 00:00:00 -0400

Deals Shaping The Medical Industry, June 2012

Fri, 22 Jun 2012 00:00:00 -0400

Deals Shaping The Medical Industry, May 2012

Wed, 23 May 2012 00:00:00 -0400

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents.

Deals Shaping The Medical Industry, April 2012

Mon, 23 Apr 2012 00:00:00 -0400

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents.

Device and Diagnostics Dealmaking Quarterly Statistics, Q4 2011

Mon, 26 Mar 2012 00:00:00 -0400

Medical device companies raised $800 million in the fourth quarter of 2011, and venture capital represented half of that amount. Just over $4 billion was spent to acquire medical device companies, down 50% from Q3’s $8 billion.

Deals Shaping The Medical Industry (03/2012)

Mon, 26 Mar 2012 00:00:00 -0400

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents.

$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications

Fri, 09 Mar 2012 00:00:00 -0500

Recent deal-making has brought larger, deeper-pocketed players into the IPF space, but Promedior still likes its approach of going it alone with Pentraxin-2-based therapies in fibrotic disease.

Deals Of The Week: Novartis/Enanta, Ligand/Retrophin, Auxilium/Actelion, Amgen/Dako

Mon, 27 Feb 2012 00:00:00 -0500

A prosaic week in biopharma deal-making leads DOTW to ponder a brain-computer interface specialist’s efforts to apply its technology to patients with severe communication limitations.

Market & Industry Briefs

Fri, 24 Feb 2012 00:00:00 -0500

Brief summaries of recent medtech market and industry developments. This month we cover news from the TAVI space, ConforMIS’ customized knee implants, and Siemens’ recent companion diagnostic dealmaking.

Deals Shaping the Medical Industry (2/2012)

Fri, 24 Feb 2012 00:00:00 -0500

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents.

Biopharma Out-licensing: 2012’s “In” Thing?

Mon, 13 Feb 2012 00:00:00 -0500

Talk to any Big Pharma business development executive about deal-making trends for more than 15 minutes and the word out-licensing is bound to crop up. Major drugmakers are moving beyond the rhetoric and actually giving up rights to individual assets that heretofore would have been deemed too valuable to merit out-licensing -- but with qualifications.

Deals Of The Week: Amgen/Micromet, Celgene/Avila, Watson/Ascent

Mon, 30 Jan 2012 00:00:00 -0500

Along with three biotech acquisitions, the week in deal-making also saw the licensing of a new hepatitis C candidate with a different mechanism of action, further consolidation in the animal health field, and the end of Ipsen and Santhera’s collaboration on Alzheimer’s drug fipamezole.